Sepsis Diagnostics Market for Blood Culture Media Segment to Grow Significantly During 2021-2028

According to our new research study on "Sepsis Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Product, Technology, Method, Test Type, Pathogen, and End User," the market is expected to grow from US$ 661.83 million in 2021 to US$ 1,226.52 million by 2028; it is estimated to grow at a CAGR of 9.2% from 2021 to 2028. The report highlights trends prevailing in the market and factors governing the growth of the market. Rising demand for rapid diagnostic tests leading to increasing product launches is expected to accelerate the overall sepsis diagnostics market revenue during the forecast period. However, the lack of skilled professionals limits the market growth.

Most of the diagnostic tests for sepsis are time-consuming and take up to 72 hours to provide results. In the era of molecular diagnosis for every kind of disease, the demand for rapid diagnostic tests for sepsis is rising. To fulfill this rising demand, many key players operating in the industry put efforts into developing innovative rapid diagnostic tests for sepsis. For instance, in September 2020, Barcelona-based Loop Diagnostics launched a point-of-care diagnosis platform. The platform aimed to replace the traditional methods of blood culture analysis and provide rapid results. Also, it can identify bacterial infections via blood-based markers and provide test results in two hours with a 99% accuracy rate. The cost of the diagnosis with this system is US$ 70. Moreover, the key players developed cost-effective diagnostic tests to overcome all the challenges associated with sepsis diagnosis. For instance, Inflammatix, a pioneering molecular diagnostics company, announced the publication of a health economic model that shows the use of the company's HostDxTM Sepsis test is cost-effective as compare to standard methods. The test was performed on patients suspected of acute respiratory tract infections (ARTI) in Emergency Departments. The study was published in April 2020 in The Journal of Health Economics and Outcomes Research. The model informed hospital clinicians of the potential clinical and economic benefits of widespread adoption of the HostDx Sepsis test.

Additionally, in May 2020, Beckman Coulter announced the launch of its new DxH 690T hematology analyzer with early sepsis indicators in the US. The DxH 690T reported accurate results and improved turnaround time by reducing procedural steps and manual touchpoints, making it an ideal solution to help relieve some of sepsis disease burden. Thus, the rising in demand for rapid diagnostics test led to product launches is expected to drive the sepsis diagnostics market during the forecast period.

On the other hand, the lack of skilled professionals hinders market size and growth. Sepsis diagnosis requires laboratory skills and proficiency to process the collection and investigation of the clinical sample. Sepsis is a life-threatening illness that needs to be diagnosed and treated at the earliest with the help of skilled healthcare professionals. The lack of experienced professionals is a significant concern worldwide. For instance, according to an article published in Young Scientist Journal (YSJ) in April 2018, Sub-Saharan Africa faced a critical shortage of healthcare workers. The deficit is due to the declining emigration of healthcare professionals and the lack of proper healthcare infrastructure and medical graduates, which acts as a restraint on the development of the public health system in that region. Sub-Saharan Africa is considered to have the weakest healthcare system globally. Such restrictions are expected to hamper the growth of the global sepsis diagnostics market over the forecast period.

Technology plays a critical role in healthcare diagnostics as it offers accuracy and saves time and resources and therefore, plays a critical role acting as a future trend in sepsis diagnosis. In sepsis diagnosis process, the identification of causative pathogen is essential in selecting appropriate antibiotic therapy as a part of the treatment. Molecular diagnostics, flow cytometry, microfluidics, immunoassay, biomarkers, and microbiology are majorly used for sepsis diagnostics techniques. Therefore, several companies are investing in point-of-care molecular diagnostics to diagnose bacterial and viral pathogens early and for better patient management. For instance, in October 2020, Immunexpress launched a rapid SeptiCyte, a one-hour molecular diagnostic test for sepsis in Europe on Biocartis' Idylla platform.

Based on product, the sepsis diagnostics market is segmented into instruments, reagents and assays, blood culture media, and software. The blood culture media segment led the market in 2021 and is expected to retain its dominance during the forecast period. According to the Journal of the Academy of Clinical Microbiologists report, blood culture media remains one of the most critical investigations in the sepsis management as it allows identification of the responsible organism for sepsis, appropriate choice of empirical and specific antibiotics, and points towards further investigations for identifying the focus on infection. A blood culture media is recommended for all sepsis patients. Automation in the blood culture system has enabled maximum yield of pathogens in the shortest possible time to improve patient management and save lives. 30-60% of blood culture media in sepsis become positive. The method is highly recommended as it reveals one of the highest levels of evidence in the diagnostic workup of a sepsis patient. Such factors would support the market growth for the blood culture media segment during the forecast period.

Abbott; F. HOFFMANN-LA ROCHE LTD.; Immunexoress, Inc.; BD; Danaher (Beckman Coulter); Luminex Corporation; Thermo Fischer Scientific Inc.; bioMerieux Inc.; T2 Biosystems, Inc.; and Axis-Shield Diagnostics Ltd are among the leading companies operating in the sepsis diagnostics market.

The report segments the sepsis diagnostics market as follows:

The sepsis diagnostics market is segmented on the basis of product, technology, method, test type, pathogen, and end user. Based on product, the market is segmented into instruments, reagents and assays, blood culture media, and software. Based on technology, the sepsis diagnostics market is segmented into molecular diagnostics, flow cytometry, microfluidics, immunoassay, biomarkers, and microbiology. By method, the market is bifurcated into automated diagnostics and conventional diagnostics. By pathogen, the sepsis diagnostics market is segmented into bacterial sepsis, fungal sepsis, and others. By end user, the market is segmented into hospitals, pathology and reference laboratories, and others.

By geography, the global sepsis diagnostics market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of APAC), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of MEA), and South & Central America (Brazil, Argentina, and the Rest of South and Central America.

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com